Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-TT Antibody Persistence and Booster Study
NCT01934140Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2014
- Primary completion
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen in meningococcal disease, sponsored by Pfizer. Started Apr 2014; status: completed.
02
Drugs
Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01934140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01934140.